Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2015

Conditions
Leukemia, Myelocytic, AcuteLeukemia, Lymphocytic, AcuteLeukemia, Myeloid, ChronicMyelodysplastic Syndromes
Interventions
DRUG

Tacrolimus

"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."

DRUG

Methotrexate

Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.

DRUG

Sirolimus

"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged \< 12.0 years OR weighing \< 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."

Trial Locations (24)

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute, Pittsburgh

19104

University of Pennsylvania Cancer Center, Philadelphia

23298

Virginia Commonwealth University/MCV Hospital, Richmond

27705

Duke University Medical Center, Durham

30322

Emory University, Atlanta

32610

University of Florida College of Medicine (Shands), Gainesville

43210

Ohio State, Arthur G. James Cancer Hospital, Columbus

46202

Indiana University Medical Center, Indianapolis

55455

University of Minnesota, Minneapolis

55905

Mayo Clinic, Rochester

63110

Washington University/Barnes Jewish Hospital, St Louis

73104

University of Oklahoma Medical Center, Oklahoma City

78229

Texas Transplant Institute, San Antonio

91010

City of Hope National Medical Center, Duarte

92093

UCSD Medical Center, La Jolla

94305

Stanford Hospital and Clinics, Stanford

97239

Oregon Health & Science University, Portland

52242-1009

University of Iowa Hospitals and Clinics, Iowa City

02114

DFCI/Brigham & Women's Hospital, Boston

48109-0914

University of Michigan Medical Center, Ann Arbor

44106-5061

University Hospitals of Cleveland/Case Western, Cleveland

53792-5156

University of Wisconsin Hospital & Clinics, Madison

CEDEX 10

Hopital Saint-Louis, Paris

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Blood and Marrow Transplant Clinical Trials Network

NETWORK

collaborator

National Cancer Institute (NCI)

NIH

lead

Medical College of Wisconsin

OTHER

NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | Biotech Hunter | Biotech Hunter